Latest news with #NewronPharmaceuticalsS.p.A
Yahoo
05-04-2025
- Business
- Yahoo
Newron Pharmaceuticals S.p.A. Just Missed EPS By 53%: Here's What Analysts Think Will Happen Next
Shareholders in Newron Pharmaceuticals S.p.A. (VTX:NWRN) had a terrible week, as shares crashed 23% to CHF6.15 in the week since its latest full-year results. Results were mixed, with revenues of €51m exceeding expectations, even as statutory earnings per share (EPS) fell badly short. Earnings were €0.85 per share, -53% short of analyst expectations. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. We've gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. Taking into account the latest results, the current consensus, from the two analysts covering Newron Pharmaceuticals, is for revenues of €11.3m in 2025. This implies a substantial 78% reduction in Newron Pharmaceuticals' revenue over the past 12 months. The company is forecast to report a statutory loss of €1.70 in 2025, a sharp decline from a profit over the last year. In the lead-up to this report, the analysts had been modelling revenues of €13.5m and earnings per share (EPS) of €0.16 in 2025. So we can see that the consensus has become notably more bearish on Newron Pharmaceuticals' outlook following these results, with a substantial drop in next year's revenue estimates. Furthermore, they expect the business to be loss-making next year, compared to their previous calls for a profit. Check out our latest analysis for Newron Pharmaceuticals The average price target was broadly unchanged at CHF15.32, perhaps implicitly signalling that the weaker earnings outlook is not expected to have a long-term impact on the valuation. These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the Newron Pharmaceuticals' past performance and to peers in the same industry. These estimates imply that revenue is expected to slow, with a forecast annualised decline of 78% by the end of 2025. This indicates a significant reduction from annual growth of 37% over the last five years. By contrast, our data suggests that other companies (with analyst coverage) in the same industry are forecast to see their revenue grow 3.7% annually for the foreseeable future. It's pretty clear that Newron Pharmaceuticals' revenues are expected to perform substantially worse than the wider industry. The most important thing to take away is that the analysts are expecting Newron Pharmaceuticals to become unprofitable next year. Unfortunately, they also downgraded their revenue estimates, and our data indicates underperformance compared to the wider industry. Even so, earnings per share are more important to the intrinsic value of the business. The consensus price target held steady at CHF15.32, with the latest estimates not enough to have an impact on their price targets. Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. We have analyst estimates for Newron Pharmaceuticals going out as far as 2027, and you can see them free on our platform here. Plus, you should also learn about the 3 warning signs we've spotted with Newron Pharmaceuticals (including 2 which shouldn't be ignored) . Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
Yahoo
17-03-2025
- Business
- Yahoo
Those who invested in Newron Pharmaceuticals (VTX:NWRN) three years ago are up 548%
Newron Pharmaceuticals S.p.A. (VTX:NWRN) shareholders have seen the share price descend 17% over the month. But that doesn't change the fact that the returns over the last three years have been spectacular. Indeed, the share price is up a whopping 548% in that time. So you might argue that the recent reduction in the share price is unremarkable in light of the longer term performance. The thing to consider is whether there is still too much elation around the company's prospects. We love happy stories like this one. The company should be really proud of that performance! So let's investigate and see if the longer term performance of the company has been in line with the underlying business' progress. See our latest analysis for Newron Pharmaceuticals Newron Pharmaceuticals wasn't profitable in the last twelve months, it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). Arguably revenue is our next best option. When a company doesn't make profits, we'd generally hope to see good revenue growth. Some companies are willing to postpone profitability to grow revenue faster, but in that case one would hope for good top-line growth to make up for the lack of earnings. Over the last three years Newron Pharmaceuticals has grown its revenue at 16% annually. That's pretty nice growth. Some shareholders might think that the share price rise of 86% per year is a lucky result, considering the level of revenue growth. After a price rise like that many will have the business, and plenty of them will be wondering whether the price moved too high, too fast. The company's revenue and earnings (over time) are depicted in the image below (click to see the exact numbers). Take a more thorough look at Newron Pharmaceuticals' financial health with this free report on its balance sheet. Newron Pharmaceuticals shareholders have received returns of 10% over twelve months, which isn't far from the general market return. We should note here that the five-year TSR is more impressive, at 16% per year. More recently, the share price growth has slowed. But it has to be said the overall picture is one of good long term and short term performance. Arguably that makes Newron Pharmaceuticals a stock worth watching. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Even so, be aware that Newron Pharmaceuticals is showing 3 warning signs in our investment analysis , and 2 of those are concerning... We will like Newron Pharmaceuticals better if we see some big insider buys. While we wait, check out this free list of undervalued stocks (mostly small caps) with considerable, recent, insider buying. Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Swiss exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
Yahoo
11-03-2025
- Business
- Yahoo
Newron Pharmaceuticals to Participate in a Fireside Chat at the 37th Annual ROTH Conference
MILAN, Italy & MORRISTOWN, N.J., March 11, 2025--(BUSINESS WIRE)--Newron Pharmaceuticals S.p.A. ("Newron") (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for diseases of the central and peripheral nervous system, today announced that Stefan Weber, CEO, will participate in a fireside chat at the 37th Annual ROTH Conference on Monday, March 17 at 11:30 a.m. PDT. A live audio webcast of the fireside chat can be accessed on the ROTH Conference website here. About Newron Pharmaceuticals Newron (SIX: NWRN, XETRA: NP5) is a biopharmaceutical company focused on developing novel therapies for patients with diseases of the central and peripheral nervous system. Headquartered in Bresso, near Milan, Italy, Newron is advancing its lead compound, evenamide, a first-in-class glutamate modulator, which has the potential to be the first add-on therapy for treatment-resistant schizophrenia (TRS) and for poorly responding patients with schizophrenia. Evenamide is currently in Phase III development and clinical trial results to date demonstrate the benefits of this drug candidate in the TRS patient population, with significant improvements across key efficacy measures increasing over time, as well as a favourable safety profile, which is uncommon for available first- and second-generation antipsychotic medications. Newron has signed development and commercialization agreements for evenamide with EA Pharma (a subsidiary of Eisai) for Japan and other Asian territories, as well as Myung In Pharm for South Korea. Newron has a proven track record in bringing CNS therapies to market. Its Parkinson's disease treatment, Xadago® (safinamide), is approved in over 20 markets, including the USA, UK, EU, Switzerland, and Japan, and commercialized in partnerships with Zambon and Meiji Seika. For more information, please visit: View source version on Contacts For more information, please contact: Newron Stefan Weber – CEO+39 02 6103 46 26pr@ UK/Europa Simon Conway / Ciara Martin / Natalie Garland-Collins, FTI Consulting+44 20 3727 1000SCnewron@ Switzerland Valentin Handschin, IRF+41 43 244 81 54handschin@ Germany/Europa Anne Hennecke / Maximilian Schur, MC Services+49 211 52925227newron@ USA Paul Sagan, LaVoieHealthScience+1 617 374 8800, Ext. 112psagan@
